The new US patent, which has 22 claims, includes assessment of heart rate in zebrafish and use of microplates for high-throughput screening.
Patricia McGrath, president and CEO of Phylonix, said: “Although the pharmaceutical industry and the FDA have increased scrutiny of drug-related cardiotoxicity, especially drug effects on prolonging QT interval, there is currently a gap in technologies for preclinical cardiotoxicity assessment. Our panel of zebrafish-based assays will bridge this gap by enabling thorough assessment of cardiotoxicity during early stages of drug development.”
“This award complements our previously issued patents for assessing angiogenesis, apoptosis, and toxicity in zebrafish, use of high-throughput screening methods, and transplantation of human cells for drug testing and disease modeling.”